EVIDENCE-BASED MEDICINE
Developing and Testing Adaptive Treatment Strategies Using Substance-Induced Psychosis as an Example
By Ree Dawson, Alan I. Green, Robert E. Drake, Thomas H. McGlashan, Bella Schanzer, Philip W. Lavori
Development of Antagonists of the Platelet-Derived Growth Factor Receptor Family
By Neill A. Giese, PhD, Nathalie A. Lokker, PhD, Jin-Chen Yu, PhD, Kenji Matsuno, PhD, Michio Ichimura, PhD, Shoji Oda, PhD, Robert Scarborough, PhD, and Anjali Pandey, PhD
Development of STI571 and Its Use in Chronic Myelogenous Leukemia and Other Malignancies
By Michael J. Mauro, MD, Michael E. O’Dwyer, MD, and Brian J. Druker, MD
Diagnosis and Staging of Gynecological Malignancies
By Brigitte E. Miller, MD
Diagnosis and Treatment of Depression in the Cancer Patient
Tracy L. Skaer, PharmD, Linda M. Robison, MSPH, David A. Sclar, PhD
Diferencias de género en el trastorno depresivo mayor y el trastorno bipolar
Dra. Ellen Leibenluft
Divalproex and Epilepsy
By L. James Willmore, MD
Divalproex in the Treatment of Bipolar Disorder
By Paul E. Keck, Jr, MD, and Susan L. McElroy, MD
Divalproex in the Treatment of Migraine
By Frederick G. Freitag, DO
Does Isotretinoin Cause Depression and Suicide?
By J. Douglas Bremner, MD
¡Bienvenidos a
Psiquiatría y Salud Integral!
Dr. Juan E. Mezzich y Dr. Miguel R. Jorge
Drug Development for Anxiety Disorders: New Roles for Atypical Antipsychotics
By William H. Carson, MD, Hisashi Kitagawa, PhD, and Charles B. Nemeroff, MD, PhD
COMPLICATED CASE HISTORIES
Drug Induced Mania in a Boy with High Functioning Autism
By Mustafa Deniz Tutkunkardas, Nahit Motavalli Mukaddes
Drug–Drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients
By Robert R. Conley, MD and Deanna L. Kelly, PharmD, BCPP
Duloxetine for the Treatment of Major Depressive Disorder
By Charles B. Nemeroff, MD, PhD, Alan F. Schatzberg, MD, David J. Goldstein, MD, PhD, Michael J. Detke, MD, PhD, Craig Mallinckrodt, PhD, Yili Lu, PhD, and Pierre V. Tran, MD
Duloxetine in Military Posttraumatic Stress Disorder
By Gerardo Villarreal, José M. Cañive, Lawrence A. Calais, Gregory Toney, Ashley K. Smith
Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
Economic Impacts of Anxiety Disorders
By Ernst R. Berndt, PhD and Tamar Sisitsky, MA
Economics of Cancer Drug Development
By Michael Dickson, PhD, and Gene Reeder, PhD
EDITOR’S LETTER
Charles B. Nemeroff, MD, PhD
Effectiveness of a Brain-Computer Interface Based Programme for the Treatment of ADHD: A Pilot Study
By Choon Guan Lim, Tih-Shih Lee, Cuntai Guan, Daniel Shuen Sheng Fung, Yin Bun Cheung, Stephanie Sze Wei Teng, Haihong Zhang, K Ranga Krishnan
Effectiveness of Clozapine use in Delaying Hospitalization in Routine Clinical Practice: A 2 year Observational Study
By Kazare Nyakyoma, Richard Morriss
Effects of Discontinuation of Paliperidone Long-Acting Injectable After Switching from Risperidone Long-Acting Injectable Switching
By Takafumi Watanabe, Atsurou Yamada
Efficacy and Tolerability of Controlled-Release Paroxetine
By Robert N. Golden, MD